Jacobs & Co. CA grew its holdings in Amgen Inc. (NASDAQ:AMGN) by 0.8% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 38,904 shares of the medical research company’s stock after buying an additional 292 shares during the period. Jacobs & Co. CA’s holdings in Amgen were worth $9,679,000 as of its most recent filing with the Securities & Exchange Commission.
Other hedge funds and other institutional investors have also modified their holdings of the company. Advisory Alpha LLC acquired a new stake in shares of Amgen in the third quarter valued at about $25,000. Fort Pitt Capital Group LLC acquired a new stake in Amgen during the fourth quarter worth about $28,000. Norway Savings Bank acquired a new stake in Amgen during the fourth quarter worth about $29,000. Crescent Capital Consulting LLC acquired a new stake in Amgen during the fourth quarter worth about $34,000. Finally, Kinloch Capital LLC acquired a new stake in Amgen during the fourth quarter worth about $40,000. Institutional investors and hedge funds own 75.23% of the company’s stock.
In related news, Director Ronald D. Sugar sold 1,000 shares of Amgen stock in a transaction that occurred on Wednesday, January 13th. The shares were sold at an average price of $235.99, for a total value of $235,990.00. Following the completion of the transaction, the director now owns 16,805 shares in the company, valued at $3,965,811.95. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Jonathan P. Graham sold 11,110 shares of Amgen stock in a transaction that occurred on Thursday, February 4th. The stock was sold at an average price of $236.51, for a total transaction of $2,627,626.10. The disclosure for this sale can be found here. In the last three months, insiders sold 14,360 shares of company stock valued at $3,393,044. Insiders own 0.36% of the company’s stock.
Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Monday, February 1st. The medical research company reported $3.81 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $3.39 by $0.42. Amgen had a net margin of 29.42% and a return on equity of 95.55%. The business had revenue of $6.63 billion during the quarter, compared to analyst estimates of $6.57 billion. During the same quarter last year, the firm posted $3.64 earnings per share. The business’s revenue for the quarter was up 7.1% compared to the same quarter last year. Analysts anticipate that Amgen Inc. will post 16.15 EPS for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 8th. Stockholders of record on Monday, May 17th will be paid a $1.76 dividend. This represents a $7.04 annualized dividend and a dividend yield of 2.84%. The ex-dividend date of this dividend is Friday, May 14th. Amgen’s payout ratio is 47.50%.
Several equities research analysts recently issued reports on AMGN shares. Oppenheimer raised their price objective on shares of Amgen from $266.00 to $275.00 in a research report on Monday. Cantor Fitzgerald raised their price objective on shares of Amgen from $280.00 to $295.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 3rd. Piper Sandler cut their price objective on shares of Amgen from $280.00 to $260.00 and set an “overweight” rating for the company in a research report on Wednesday, February 3rd. JPMorgan Chase & Co. set a $222.00 price objective on shares of Amgen and gave the stock a “neutral” rating in a research report on Thursday, March 4th. Finally, Barclays cut their price objective on shares of Amgen from $242.00 to $230.00 and set an “equal weight” rating for the company in a research report on Thursday, March 11th. Ten analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $258.57.
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with BehÃ§et's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization.
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.